H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Cognition Therapeutics (CGTX) to $3 from $5 and keeps a Buy rating on the shares. The firm cites the anticipated equity dilution later this year to extend the company’s operational runway for the target cut. Zervimesine appears applicable across multiple fronts, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGTX:
- Cognition Therapeutics presents preclinical data on zervimesine at ARVO
- Cognition Therapeutics Reports Q1 2025 Financials and Progress
- Cognition Therapeutics reports results from Phase 2 COG2201 trial
- Cognition Therapeutics Announces Positive Phase 2 Trial Results
- Cognition Therapeutics reports Q1 EPS (14c), consensus (12c)